Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers
Portfolio Pulse from
Salarius Pharmaceuticals announced the resumption of patient enrollment in a Phase 1/2 clinical trial for seclidemstat combined with azacitidine to treat hematologic cancers. The trial is conducted at MD Anderson Cancer Center.
February 03, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Salarius Pharmaceuticals is resuming patient enrollment in a clinical trial for seclidemstat with azacitidine, potentially advancing treatment options for hematologic cancers.
The resumption of patient enrollment in the clinical trial is a positive development for Salarius Pharmaceuticals, as it indicates progress in their research and potential future treatment options. This could lead to increased investor confidence and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100